Bringing the fundamentals into focus…
Bringing the fundamentals into focus…
ERAS · against 588 other Healthcare companies listed in US-listed
Ranked #313 of 589 · scores higher than 3% of peers
Bars: peers in each 10-point band of the valuation score277 peers with a valuation score of 0–9, including ERAS · Click a bar to see the companies
Mainly because of its earnings yield, EBITDA yield and free cash flow yield, which are weaker than most Healthcare peers.
| Metric | ERAS | Peer median | Better than | Position among peers | Weight |
|---|---|---|---|---|---|
| Earnings yieldHigher is better · 577 reported | -6.5% | -4.3% | 44% | 30% | |
| EBITDA yieldHigher is better · 578 reported | -3.0% | -0.8% | 44% | 50% | |
| Free cash flow yieldHigher is better · 553 reported | -4.9% | -2.3% | 41% | 20% | |
| Book yieldHigher is better · 587 reported | 7.9% | 25.9% | 22% | Context only |
| Rank | Company | Market cap | Valuation | Overall |
|---|---|---|---|---|
| 1 | 256M USD | 98 | 80 | |
| 2 | 595M USD | 96 | 97 | |
| 2 | 433M USD | 96 | 81 | |
| 2 | 289M USD | 96 | 57 | |
| 2 | 810M USD | 96 | 69 | |
| 313 | 302M USD | 8 | 17 | |
| 313 | 530M USD | 8 | 23 | |
| 313 | 487M USD | 8 | 29 | |
| 313 | 455M USD | 8 | 36 | |
| 313 | 5.1B USD | 8 | 35 | |
| 313 | 1.8B USD | 8 | 31 | |
| 313 | 486M USD | 8 | 16 | |
| 313 | 551M USD | 8 | 27 | |
| 313 | 4.1B USD | 8 | 42 |
Scores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score